Ociperlimab Terminated Phase 3 Trials for Non-Small Cell Lung Cancer (NSCLC) Treatment

Indications	Status	Purpose	Phase
DBCOND0034130 (Non-Small Cell Lung Cancer (NSCLC))	Terminated	Treatment	3

clinicaltrials.gov Identifier	Title	Drugs
NCT04866017	A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer	Durvalumab (DB11714) Ociperlimab (DB18947) Tislelizumab (DB14922)